INNPF — INNOCAN PHARMA Corp
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1889791 ·
Canada (Federal Level)
Last close
$1.62
Market Cap
$7.29M
52W High
$14.26
52W Low
$1.43
ADV30
15
Next earnings
2026-11-25
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,250,000 | 4,769,000 | -508,000 | -34,000 | 10,365,000 | 6,399,000 | 2,953,000 |
| Mar 2026 | 6,465,000 | 5,890,000 | -786,000 | -972,000 | 10,845,000 | 6,627,000 | 2,918,000 |
| Dec 2025 | 4,988,000 | 4,430,000 | -922,000 | 1,995,000 | 10,522,000 | 6,687,000 | 2,285,000 |
| Sep 2025 | 6,822,000 | 6,191,000 | -1,218,000 | -1,947,000 | 11,117,000 | 7,270,000 | 4,485,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-379,000
Investing CF
$-11,000
Financing CF
$600,000
CapEx
$-16,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.84
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-37,004,000
Inventory
$2,178,000
Receivables
$1,301,000
ST Investments
—
EBIT TTM
$-542,000
Pretax Income TTM
$-770,000
Interest Exp TTM
$17,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$23,525,000
EBITDA
$-3,398,000
Free Cash Flow
$-2,346,250
Enterprise Value
$5,746,851
Total Cash
$6,399,000
Total Debt
$1,664,000
Shares Out
4,498,772
Trailing EPS
$-0.21
Book Value
$1.16
ROE
-11.8%
ROA
-20.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 26,612,000 | -1,255,000 | -1,124,000 | 10,522,000 | 2,285,000 | 5,599,000 | 495,000 |
| Dec 2024 | 29,437,000 | -1,247,000 | -1,834,000 | 9,260,000 | 2,238,000 | 5,167,000 | -1,579,000 |
| Dec 2023 | 13,657,000 | -3,803,000 | -4,700,000 | 6,940,000 | 2,554,000 | 4,103,000 | -3,904,000 |
| Dec 2022 | 2,559,000 | -6,266,000 | -3,764,000 | 6,976,000 | 751,000 | 6,394,000 | -6,067,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CNSP | CNS Pharmaceuticals, Inc. | $7.21M | $4.93 | — |
| SKYE | Skye Bioscience, Inc. | $7.39M | $1.67 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.43M | $4.74 | — |
| INM | InMed Pharmaceuticals Inc. | $7.58M | $1.38 | — |
| LEXX | Lexaria Bioscience Corp. | $6.91M | $3.28 | — |
News headlines (Yahoo Finance, 1h cache)
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
2026-05-27 20:00 · Yahoo
Innocan Pharma Announces First Tranche Closing of Private Placement of Units
2026-09-23 20:01 · Yahoo
Innocan Pharma Announces Private Placement of Units
2026-09-09 20:36 · Yahoo
Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue of US$5.25M (CAD 7.3M)
2026-08-31 20:01 · Yahoo
Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust
2026-08-05 13:30 · Yahoo
Valitic Surpasses 2 Million Trusted Customers, Marking a Major Milestone in Its Consumer Wellness Growth
2026-07-29 20:00 · Yahoo
Innocan Pharma LPT-CBD is featured in Pain Medicine News
2026-05-06 20:01 · Yahoo
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
2026-02-09 14:07 · Yahoo
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
2026-01-27 21:00 · Yahoo
Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering
2025-12-10 15:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.